GSK3 regulates the expressions of human and mouse c-Myb via different mechanisms
© Kitagawa et al; licensee BioMed Central Ltd. 2010
Received: 1 September 2010
Accepted: 21 November 2010
Published: 21 November 2010
c-Myb is expressed at high levels in immature progenitors of all the hematopoietic lineages. It is associated with the regulation of proliferation, differentiation and survival of erythroid, myeloid and lymphoid cells, but decreases during the terminal differentiation to mature blood cells. The cellular level of c-Myb is controlled by not only transcriptional regulation but also ubiquitin-dependent proteolysis. We recently reported that mouse c-Myb protein is controlled by ubiquitin-dependent degradation by SCF-Fbw7 E3 ligase via glycogen synthase kinase 3 (GSK3)-mediated phosphorylation of Thr-572 in a Cdc4 phosphodegron (CPD)-dependent manner. However, this critical threonine residue is not conserved in human c-Myb. In this study, we investigated whether GSK3 is involved in the regulatory mechanism for human c-Myb expression.
Human c-Myb was degraded by ubiquitin-dependent degradation via SCF-Fbw7. Human Fbw7 ubiquitylated not only human c-Myb but also mouse c-Myb, whereas mouse Fbw7 ubiquitylated mouse c-Myb but not human c-Myb. Human Fbw7 mutants with mutations of arginine residues important for recognition of the CPD still ubiquitylated human c-Myb. These data strongly suggest that human Fbw7 ubiquitylates human c-Myb in a CPD-independent manner. Mutations of the putative GSK3 phosphorylation sites in human c-Myb did not affect the Fbw7-dependent ubiquitylation of human c-Myb. Neither chemical inhibitors nor a siRNA for GSK3β affected the stability of human c-Myb. However, depletion of GSK3β upregulated the transcription of human c-Myb, resulting in transcriptional suppression of γ-globin, one of the c-Myb target genes.
The present observations suggest that human Fbw7 ubiquitylates human c-Myb in a CPD-independent manner, whereas mouse Fbw7 ubiquitylates human c-Myb in a CPD-dependent manner. Moreover, GSK3 negatively regulates the transcriptional expression of human c-Myb but does not promote Fbw7-dependent degradation of human c-Myb protein. Inactivation of GSK3 as well as mutations of Fbw7 may be causes of the enhanced c-Myb expression observed in leukemia cells. We conclude that expression levels of human and mouse c-Myb are regulated via different mechanisms.
The leucine zipper transcription factor c-Myb is expressed at high levels in immature progenitors of all the hematopoietic lineages, and is essential for fetal liver hematopoiesis, erythroid and myeloid bone marrow colony formation, and T- and B-cell development [1–4]. Moreover, elevated c-Myb expression is associated with hematological malignancies and has been reported in many cases of acute myeloblastic and lymphoblastic leukemias [1, 5–7]. The keys to the control of c-Myb protein function are post-transcriptional modifications. The c-Myb protein is phosphorylated by several kinases such as MAPK, Nemo-like kinase (NLK) and glycogen synthase kinase 3 (GSK3) [8–10]. It has been reported that phosphorylation influences the activity and stability of the c-Myb protein [11–17]. The stabilities of many kinds of cellular proteins are often controlled by the ubiquitin proteasome system, a rapid and selective degradation mechanism in cells . A previous study indicated that the stability of c-Myb protein is also regulated by this system. Especially, SCF-type E3 ubiquitin ligases target various important cellular proteins including cell cycle regulators, oncogene and tumor suppressor gene products [19, 20]. Recently, we and another group reported that the mouse c-Myb protein levels are regulated by ubiquitin-dependent degradation via SCF-Fbw7 E3 ligase in a phosphorylation-dependent manner [21, 22]. Fbw7 targets various proteins, including cyclin E, Notch1, c-Myc, SREBP, c-Jun and SRC-3, for ubiquitylation. These substrates contain a consensus phospho-binding motif for Fbw7, termed the Cdc4 phosphodegron (CPD) . Furthermore, we found that mouse c-Myb Thr-572, which is located in a domain equivalent to the CPD, is phosphorylated by GSK3, thereby allowing recognition by Fbw7 and subsequent promotion of ubiquitin-dependent degradation in the 26 S proteasome . Regarding the regulatory system of human c-Myb, it is unclear whether GSK3 is involved in the control of human c-Myb stability, although we have noticed that human c-Myb is also degraded by Fbw7. In the present study, we analyzed the regions responsible for human c-Myb ubiquitylation by SCF-Fbw7. We also investigated whether repression of GSK3 affected the stability and/or expression of human c-Myb. We found that GSK3 is not involved in human c-Myb protein stability, but plays a role in its transcriptional suppression.
Materials and methods
HEK293 and HeLa cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum. K562 cells were maintained in RPMI1640 supplemented with 10% fetal bovine serum.
The antibodies used in this study were anti-Myc antibody 9B11 (Cell Signaling), anti-Myc antibody 9E10 (Roche), anti-FLAG antibody M2 (Sigma), anti-HA antibody 12CA5 (Roche), anti-c-Myb antibody 1-1 (UPSTATE), anti-Fbw7 antibody H-300 (Santa Cruz) and anti-α-tubulin antibody DM1A (Sigma).
Complementary DNAs encoding mouse and human c-Myb wild type and their mutants were cloned into pcDNA3.1/Myc-His (Invitrogen) . Expression plasmid of ubiquitin (pCGN-HA-Ub) was previously described . Expression plasmids of pCGN-HA-human-Fbw7 and pcDNA3-FLAG-mouse-Fbw7α were kindly provided by Keiichi Nakayama, Kyushu University. All deletion and point mutants of c-Myb were constructed using standard recombinant DNA techniques.
For immunoprecipitation (IP), cell lysates were incubated with 2 μg of antibodies and protein G+ Sepharose 4FF (GE healthcare) at 4°C for 1 h. Immunocomplexes were washed five times with lysis buffer. For double IP, the first immunocomplexes, which were prepared with anti-Myc antibody, were denatured by treatment with SDS sample buffer at 100°C for 8 min. Then ubiquitylated c-Myb was immunoprecipitated again with anti-Myc antibody. Immunoprecipitated samples as well as the original cell lysates (input) were separated by SDS-PAGE and transferred from the gel onto a PVDF membrane (Millipore), followed by immunoblotting (IB). Proteins were visualized using an enhanced chemiluminescence system (Perkin Elmer).
In vivo ubiquitylation assay
All plasmids were transfected into HEK293 cells by the calcium phosphate method. As described in previous reports , to induce accumulation of polyubiquitylated c-Myb, cells were treated with the proteasome inhibitor MG132 (20 μM), for 5 h starting at 43 h after transfection and then harvested. Cell lysates were prepared with lysis buffer (50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 0.5% Triton X100, 10 μg/mL each of antipain, pepstatin, E-64, leupeptin, and trypsin inhibitor and 2.5 μg/mL of chymostatin) following IB analysis.
In vivo degradation assay
All plasmids were transfected into HeLa cells with the use of Lipofectamine 2000 (Invitrogen). A total of 24 h after transfection, each transfectant was divided into 5 culture dishes for the chase experiment, and after an additional 24 h or 48 h, cells were treated with 12.5 μg/mL of cycloheximide for the indicated times. Cell lysates were subjected to immunoblotting. The intensity of the bands was quantitated using image analysis software Image Gauge 4.21 (Fujifilm), and the signal intensity of each c-Myb was normalized using the individual levels of α-tubulin.
GSK3 inhibitor treatment
At 48 h after transfection of the expression plasmids, HeLa cells were cultured in the presence of 60 μM of 2-thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole (GSK3 inhibitor type II, Calbiochem), 30 μM of 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763, Tocris) or dimethyl sulfoxide (DMSO, vehicle control) for 24 h before treatment of cycloheximide.
K562 cells were transfected with siRNA oligonucleotides using HiPerFect transfection reagent (Qiagen) according to the manufacturer's protocol. At 48 h after transfection, cells were divided into two and subjected to IB and QRT-PCR analysis. For the degradation assay, 6 h after transfection, each transfectant was divided into 4 culture dishes. After 42 h additional hours, cells were treated with 12.5 μg/mL of cycloheximide for the indicated times. Cell lysates were subjected to IB. The nucleotide sequences of siRNA for GSK3β was 5'- GUAAUCCACCUCUGGCUAC -3' with 3' dTdT overhangs. It encodes the same sequences that it was reported before .
Quantitative real time-PCR (QRT-PCR) analysis
Total RNA was isolated from cells with the use of Isogen (Wako), and subjected to reverse transcription with random hexanucleotide primers and SuperScript Reverse Transcriptase II (Invitrogen). The resulting cDNA was subjected to QRT-PCR using the Rotor-Gene 3000 system (Corbett Research) and the SYBR premix Ex Taq kit (TaKaRa). The amount of the transcripts of interest was normalized against that of 18S rRNA as an internal standard.
Statistical significance of differences was assessed with t-test. A P value of < 0.05 was considered statistically significant.
Fbw7 promotes the degradation of human as well as mouse c-Myb
Analysis of the human c-Myb domain required for Fbw7-dependent ubiquitylation
Human Fbw7 binds to and ubiquitylates c-Myb in a CPD-independent manner, which is different from mouse Fbw7
Degradation of human c-Myb occurs in an Fbw7-dependent but a GSK3-independent manner
Depletion of GSK3β promotes the transcription of human c-Myb and represses the transcription of γ-globin in K562 cells
GSK3 is one of the coregulators for turnover of several Fbw7 substrates, including cyclin E, c-Jun, Myc, SREBP, Notch, SRC and mouse c-Myb, which have the conserved phospho-epitope known as the CPD [22, 26, 28–36]. GSK3 phosphorylates the central threonine or serine of the CPD in each substrate. This phosphorylation of the CPD is important for recognition and subsequent degradation by Fbw7. In some cases, the substrates have mutations within their CPDs, resulting in escape from Fbw7-mediated degradation [35, 37]. Retroviral Jun proteins contain mutation in their CPD, which result in the acquisition of resistance to Fbw7-dependent degradation . These mutations may contribute to increases in their oncogenic characters. Notch-activated mutations are frequently found in T-cell acute lymphoblastic leukemias (T-ALL). A point mutation at Thr-2512 surrounding the CPD in Notch has been reported as one of the mutation hotspots, and is predicted to abrogate Fbw7 binding . Because the CPDs in Fbw7 substrates play important roles for turnover, it is reasonable for them to be highly conserved across species. Nevertheless, the CPD in mouse c-Myb is not retained in human c-Myb because the equivalent aa residue to Thr-572 in the mouse c-Myb CPD is substituted by an alanine residue in human c-Myb (Figure 2A).
Human Fbw7 ubiquitylated not only human c-Myb but also mouse c-Myb, whereas mouse Fbw7 ubiquitylated mouse c-Myb but not human c-Myb. These findings suggest that human Fbw7 recognizes c-Myb in a different manner from mouse Fbw7. Two arginine mutants (R465C and R505L) of human Fbw7, which are mutated in arginine residues required for recognition of the CPD in Notch, as another substrate of Fbw7 , still bound to and ubiquitylated human c-Myb. Therefore, human Fbw7 does not require either Arg-465 or Arg-505 in the β-propeller fold for targeting of c-Myb protein as a substrate. These findings are consistent with the observation that the critical threonine residue (Thr-572) in mouse c-Myb for human Fbw7-dependent ubiquitylation is not conserved in human c-Myb. Although further structural analyses are required to fully resolve the recognition mechanism of human Fbw7 for c-Myb, our data strongly suggest that human Fbw7 ubiquitylates human c-Myb in a CPD-independent manner.
Meanwhile, it has been proposed that Fbw7 binds to and ubiquitylates cyclin E under two kinds of conditions, namely monomeric or dimeric conformations, which depend on the phosphorylation status of cyclin E containing two CPD sites [19, 39]. There may be some variety in the substrate recognition mechanism of E3.
Corradini et al.  suggested that the PI3K/Akt/GSK3β pathway is involved in the stability of human c-Myb, and found increased stabilities of two c-Myb deletion mutants (Δ(358-452) and Δ(389-418)) compared with wild type c-Myb, although the corresponding E3 ligase or phosphorylation sites were not identified. More phosphorylation sites and/or multiple kinases may be needed for the degradation of human c-Myb. Kanei-Ishii et al.  reported that the mouse c-Myb/Fbxw7 interaction was enhanced by NLK, whose recognition site (S/T-P) is also part of a consensus motif for GSK3 phosphorylation. We cannot exclude the possibility that NLK may partially contribute to the recognition of human c-Myb by Fbw7, although substitutions of the S/T-P sites to alanine or C-terminal deletion mutants that lacked some putative NLK sites did not influence the ubiquitylation ability of Fbw7 (Figure 2C, T354A, S560A, 13A, Δ498 and Δ361-497).
Elevated c-Myb expression has been reported in many cases of acute myeloblastic and lymphoblastic leukemias [6, 7]. There are several possible mechanisms underlying such increases. The first is gene amplification of c-Myb, the second is enhancement of c-Myb protein stability caused by a defect in Fbw7 resulting from a gene mutation, and the third is facilitation of gene transcription of c-Myb. Practically, there have been some reports of c-Myb gene amplification cases and frequent Fbw7 gene mutations in T-ALL [40, 35]. In this study, we found that GSK3 repressed the transcription of human c-Myb mRNA. GSK3 participates in cell cycle regulation and is a downstream target of the PI3K/Akt pathway, which inhibits GSK3 through phosphorylation of Ser-9. The PI3K/Akt pathway is activated by several kinds of growth factors. Therefore, growth factor stimuli suppress GSK3 activity via PI3K/Akt, and this may lead to enhance c-Myb expression. This mechanism is supported by our findings that depletion of GSK3 augmented c-Myb expression and repressed γ-globin expression. Alternatively, gene amplifications of PI3K have been reported in human cancer . It is possible that inactivation of GSK3 via accelerated PI3K activity leads to the induction of c-Myb transcription in leukemia. Kohmura et al.  reported that the p38 MAPK and ERK pathways are involved in the differentiation of K562 cells induced by STI571, a specific tyrosine kinase inhibitor of Abl kinase. The expression level of c-myb mRNA was clearly downregulated in K562 cells after incubation with STI571. Their findings and the present results suggest that kinase activity regulates cellular differentiation through the transcriptional repression of human c-Myb.
To investigate whether GSK3 also regulates the transcription of mouse c-Myb, we examined its influence on mouse c-Myb expression using GSK3 inhibitors. The results revealed that GSK inhibitors did not affect the transcriptional regulation of mouse c-Myb (data not shown). Moreover, we tried to confirm these results by GSK3 knockdown using mouse cell line (M-1), in which c-Myb expression was detected. However, we were unable to achieve sufficient knockdown of GSK3 for such evaluations in these cells. The species-specificity of the Fbw7 operating mechanism does appear to be an intriguing issue. However, the transcriptional regulation of c-Myb by GSK3 cannot presently be concluded to be a human-specific event.
c-Myb is abundantly expressed in immature erythroid progenitor cells, and is reduced as the cells mature. It has been observed that GATA-1, one of the erythroid lineage-specific transcriptional factors, represses c-Myb transcription through GATA-1-binding sites in the c-Myb promoter during erythroid differentiation . GATA-1 activity is regulated by post-translational systems, which include a nuclear translocation process . Hyperphosphorylated GATA-1 protein is preferentially found in the nucleus and has an enhanced DNA-binding capacity [44, 45]. Phosphorylation of GATA-1 may also have other functions, such as modulation of the binding site preferences or interactions with other transcriptional regulators. GATA-1 is phosphorylated in vivo on seven serine residues . Towatari et al.  identified MAPK as one of the kinases that acts on GATA-1, and further identified Ser-26 and Ser-178 as the phosphorylation sites for MAPK. Zhao et al.  identified the PI3K/AKT signaling pathway as a mediator of erythropoietin-induced phosphorylation of GATA-1 at Ser-310, resulting in enhancement of its transcriptional activity. They also found that the effects of AKT during the program of erythroid maturation were not limited to phosphorylation of Ser-310, and described that AKT or other PI3K-dependent kinases may phosphorylate additional sites on GATA-1. It is not yet known whether GSK3 participates in the control of GATA-1 activity. Further studies are required to elucidate the roles of kinases in the modulation of GATA-1.
Conditional inactivation of Fbw7 leads to the development of lymphoma and T-ALL in mice [49–51]. It appears that Fbw7 E3 ligase preferentially targets the regulators of hematopoiesis, such as c-Myc and Notch, which interact with Fbw7 in the GSK3-mediated phosphorylated form. Therefore, GSK3 as well as Fbw7 is important controller of the c-Myb, c-Myc and Notch protein levels for appropriate and sequential maturation of hematopoietic cells. Although it has not yet been discussed whether the GSK3 activity changes in patients with leukemia, attenuation of GSK3 activity may have a pleiotropic influence on leukemia progression through the transcriptional and post-transcriptional regulation of c-Myb.
In the mouse c-Myb protein, GSK3 phosphorylates Thr-572, leading to recognition by Fbw7 for the promotion of ubiquitin-dependent degradation. Fbw7 also promotes the ubiquitylation and proteasome-mediated degradation of human c-Myb, while GSK3 is not involved. Alternatively, GSK3 negatively regulates the transcriptional expression of human c-Myb to enhance the transcription of γ-globin, a target gene of c-Myb. Therefore, GSK3 regulates the expressions of human and mouse c-Myb via different mechanisms. Inactivation of GSK3 as well as mutations of Fbw7 may be involved in the elevated c-Myb expression observed with human leukemia development.
We thank Drs. Keiichi I. Nakayama for providing plasmids, Chiharu Uchida, Takayuki Hattori, Hayato Ihara and Toshiaki Oda for useful discussions, and Mr. Tatsuya Kobayashi, Daisuke Ichikawa and Naohiro Takamoto for their technical assistance. This work was supported in part by grants from the Ministry of Education, Science, Sports, Culture and Technology of Japan (M.K and K.K).
- Greig KT, Carotta S, Nutt SL: Critical roles for c-Myb in hematopoietic progenitor cells. Semin Immunol 2008, 4: 247–256. 10.1016/j.smim.2008.05.003View ArticleGoogle Scholar
- Friedman A: Runx1, c-Myb, and C/EBPα couple differentiation to proliferation or growth arrest during hematopoiesis. J Cell Biochem 2002, 86: 624–629. 10.1002/jcb.10271View ArticlePubMedGoogle Scholar
- Emambokus N, Vegiopoulos A, Harman B, Jenkinson E, Anderson G, Frampton J: Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb. EMBO J 2003, 22: 4478–4488. 10.1093/emboj/cdg434PubMed CentralView ArticlePubMedGoogle Scholar
- Lieu YK, Kumar A, Pajerowski AG, Rogers TJ, Reddy EP: Requirement of c-myb in T cell development and in mature T cell function. Proc Natl Acad Sci USA 2004, 101: 14853–14858. 10.1073/pnas.0405338101PubMed CentralView ArticlePubMedGoogle Scholar
- Vegiopoulos A, García P, Emambokus N, Frampton J: Coordination of erythropoiesis by the transcription factor c-Myb. Blood 2006, 107: 4703–4710. 10.1182/blood-2005-07-2968PubMed CentralView ArticlePubMedGoogle Scholar
- Slamon DJ, Boone TC, Murdock DC, Keith DE, Press MF, Larson RA, Souza LM: Studies of the human c-myb gene and its product in human acute leukemias. Science 1986, 233: 347–351. 10.1126/science.3014652View ArticlePubMedGoogle Scholar
- Siegert W, Beutler C, Langmach K, Keitel C, Schmidt CA: Differential expression of the oncoproteins c-myc and c-myb in human lymphoproliferative disorders. Eur J Cancer 1990, 26: 733–737. 10.1016/0277-5379(90)90130-LView ArticlePubMedGoogle Scholar
- Aziz N, Wu J, Dubendorff JW, Lipsick JS, Sturgill TW, Bender TP: c-Myb and v-Myb are differentially phosphorylated by p42mapk in vitro. Oncogene 1993, 8: 2259–2265.PubMedGoogle Scholar
- Kanei-Ishii C, Ninomiya-Tsuji J, Tanikawa J, Nomura T, Ishitani T, Kishida S, Kokura K, Kurahashi T, Ichikawa-Iwata E, Kim Y, Matsumoto K, Ishii S: Wnt-1 signal induces phosphorylation and degradation of c-Myb protein via TAK1, HIPK2, and NLK. Genes Dev 2004, 18: 816–829. 10.1101/gad.1170604PubMed CentralView ArticlePubMedGoogle Scholar
- Corradini F, Cesi V, Bartella V, Pani E, Bussolari R, Candini O, Calabretta B: Enhanced proliferative potential of hematopoietic cells expressing degradation-resistant c-Myb mutants. J Biol Chem 2005, 280: 30254–30262. 10.1074/jbc.M504703200View ArticlePubMedGoogle Scholar
- Lüscher B, Eisenman RN: Mitosis-specific phosphorylation of the nuclear oncoproteins Myc and Myb. J Cell Biol 1992, 118: 775–784. 10.1083/jcb.118.4.775View ArticlePubMedGoogle Scholar
- Miglarese MR, Richardson AF, Aziz N, Bender TP: Differential regulation of c-Myb-induced transcription activation by a phosphorylation site in the negative regulatory domain. J Biol Chem 1996, 271: 22697–22705. 10.1074/jbc.271.37.22697View ArticlePubMedGoogle Scholar
- Bies J, Nazarov V, Wolff L: Identification of protein instability determinants in the carboxy-terminal region of c-Myb removed as a result of retroviral integration in murine monocytic leukemias. J Virol 1999, 73: 2038–2044.PubMed CentralPubMedGoogle Scholar
- Bies J, Feiková S, Bottaro DP, Wolff L: Hyperphosphorylation and increased proteolytic breakdown of c-Myb induced by the inhibition of Ser/Thr protein phosphatases. Oncogene 2000, 19: 2846–2854. 10.1038/sj.onc.1203613View ArticlePubMedGoogle Scholar
- Bies J, Feiková S, Markus J, Wolff L: Phosphorylation-dependent conformation and proteolytic stability of c-Myb. Blood Cells Mol Dis 2001, 27: 422–428. 10.1006/bcmd.2001.0400View ArticlePubMedGoogle Scholar
- Aziz N, Miglarese MR, Hendrickson RC, Shabanowitz J, Sturgill TW, Hunt DF, Bender TP: Modulation of c-Myb-induced transcription activation by a phosphorylation site near the negative regulatory domain. Proc Natl Acad Sci USA 1995, 92: 6429–6433. 10.1073/pnas.92.14.6429PubMed CentralView ArticlePubMedGoogle Scholar
- Pani E, Ferrari S: p38MAPKδ ontrols c-Myb degradation in response to stress. Blood Cells Mol Dis 2008, 40: 388–394. 10.1016/j.bcmd.2007.09.010View ArticlePubMedGoogle Scholar
- Hershko A, Ciechanover A: The ubiquitin system. Annu Rev Biochem 1998, 67: 425–479. 10.1146/annurev.biochem.67.1.425View ArticlePubMedGoogle Scholar
- Bosu DR, Kipreos ET: Cullin-RING ubiquitin ligases: global regulation and activation cycles. Cell Div 2008, 3: 7. 10.1186/1747-1028-3-7PubMed CentralView ArticlePubMedGoogle Scholar
- Skaar JR, Pagano M: Control of cell growth by the SCF and APC/C ubiquitin ligases. Curr Opin Cell Biol 2009, 21: 816–824. 10.1016/j.ceb.2009.08.004PubMed CentralView ArticlePubMedGoogle Scholar
- Kanei-Ishii C, Nomura T, Takagi T, Watanabe N, Nakayama KI, Ishii S: Fbxw7 acts as an E3 ubiquitin ligase that targets c-Myb for nemo-like kinase (NLK)-induced degradation. J Biol Chem 2008, 283: 30540–30548. 10.1074/jbc.M804340200PubMed CentralView ArticlePubMedGoogle Scholar
- Kitagawa K, Hiramatsu Y, Uchida C, Isobe T, Hattori T, Oda T, Shibata K, Nakamura S, Kikuchi A, Kitagawa M: Fbw7 promotes ubiquitin-dependent degradation of c-Myb: involvement of GSK3-mediated phosphorylation of Thr-572 in mouse c-Myb. Oncogene 2009, 28: 2393–2405. 10.1038/onc.2009.111View ArticlePubMedGoogle Scholar
- Nakayama KI, Nakayama K: Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006, 6: 369–381. 10.1038/nrc1881View ArticlePubMedGoogle Scholar
- Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa K, Shirane M, Tsunematsu R, Tsukiyama T, Ishida N, Kitagawa M, Nakayama KI, Hatakeyama S: Targeted disruption of Skp2 results in accumulation of cyclin E and p27 Kip1 , polyploidy and centrosome overduplication. EMBO J 2000, 19: 2069–2081. 10.1093/emboj/19.9.2069PubMed CentralView ArticlePubMedGoogle Scholar
- Yamamoto H, Yoo SK, Nishita M, Kikuchi A, Minami Y: Wnt5a modulates glycogen synthase kinase 3 to induce phosphorylation of receptor tyrosine kinase Ror2. Genes Cells 2007, 12: 1215–1223. 10.1111/j.1365-2443.2007.01128.xView ArticlePubMedGoogle Scholar
- O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, Hardwick J, Welcker M, Meijerink JP, Pieters R, Draetta G, Sears R, Clurman BE, Look AT: FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors. J Exp Med 2007, 204: 1813–1824. 10.1084/jem.20070876PubMed CentralView ArticlePubMedGoogle Scholar
- Jiang J, Best S, Menzel S, Silver N, Lai MI, Surdulescu GL, Spector TD, Thein SL: cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood 2006, 108: 1077–1083. 10.1182/blood-2006-01-008912View ArticlePubMedGoogle Scholar
- Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, Elledge SJ: Phosphorylation-dependent ubiquitination of cyclin E by the SCF Fbw7 ubiquitin ligase. Science 2001, 294: 173–177. 10.1126/science.1065203View ArticlePubMedGoogle Scholar
- Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI: Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001, 413: 316–322. 10.1038/35095076View ArticlePubMedGoogle Scholar
- Ye X, Nalepa G, Welcker M, Kessler BM, Spooner E, Qin J, Elledge SJ, Clurman BE, Harper JW: Recognition of phosphodegron motifs in human cyclin E by the SCF Fbw7 ubiquitin ligase. J Biol Chem 2004, 279: 50110–50119. 10.1074/jbc.M409226200View ArticlePubMedGoogle Scholar
- Nateri AS, Riera-Sans L, Da Costa C, Behrens A: The ubiquitin ligase SCF Fbw7 antagonizes apoptotic JNK signaling. Science 2004, 303: 1374–1378. 10.1126/science.1092880View ArticlePubMedGoogle Scholar
- Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, Clurman BE: The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA 2004, 101: 9085–9090. 10.1073/pnas.0402770101PubMed CentralView ArticlePubMedGoogle Scholar
- Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K, Nakayama KI: Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004, 23: 2116–2125. 10.1038/sj.emboj.7600217PubMed CentralView ArticlePubMedGoogle Scholar
- Sundqvist A, Bengoechea-Alonso MT, Ye X, Lukiyanchuk V, Jin J, Harper JW, Ericsson J: Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF Fbw7 . Cell Metab 2005, 1: 379–391. 10.1016/j.cmet.2005.04.010View ArticlePubMedGoogle Scholar
- Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G, Ferrando A, Aifantis I: The SCF FBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007, 204: 1825–1835. 10.1084/jem.20070872PubMed CentralView ArticlePubMedGoogle Scholar
- Wu RC, Feng Q, Lonard DM, O'Malley BW: SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell 2007, 129: 1125–1140. 10.1016/j.cell.2007.04.039View ArticlePubMedGoogle Scholar
- Welcker M, Clurman BE: FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nature Rev 2008, 8: 83–93. 10.1038/nrc2290Google Scholar
- Wei W, Jin J, Schlisio S, Haroer JW, Kaelin WG: The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 2005, 8: 25–33. 10.1016/j.ccr.2005.06.005View ArticlePubMedGoogle Scholar
- Welcker M, Clurman BE: Fbw7/hCDC4 dimerization regulates its substrate interactions. Cell Div 2007, 2: 7. 10.1186/1747-1028-2-7PubMed CentralView ArticlePubMedGoogle Scholar
- Clappier E, Cuccuini W, Kalota A, Crinquette A, Cayuela JM, Dik WA, Langerak AW, Montpellier LB, Walrafen P, Delattre O, Aurias A, Leblanc T, Dombret H, Gewirtz AM, Baruchel A, Sigaux F, Soulier J: The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood 2007, 110: 1251–1261. 10.1182/blood-2006-12-064683View ArticlePubMedGoogle Scholar
- Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004, 30: 193–204. 10.1016/j.ctrv.2003.07.007View ArticlePubMedGoogle Scholar
- Kohmura K, Miyakawa Y, Kawai Y, Ikeda Y, Kizaki M: Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells. J Cell Physiol 2004, 198: 370–376. 10.1002/jcp.10426View ArticlePubMedGoogle Scholar
- Bartunek P, Králová J, Blendinger G, Dvorák M, Zenke M: GATA-1 and c-myb crosstalk during red blood cell differentiation through GATA-1 binding sites in the c-myb promoter. Oncogene 2003, 22: 1927–1935. 10.1038/sj.onc.1206281View ArticlePubMedGoogle Scholar
- Briegel K, Bartunek P, Stengl G, Lim KC, Beug H, Engel JD, Zenke M: Regulation and function of transcription factor GATA-1 during red blood cell differentiation. Development 1996, 122: 3839–3850.PubMedGoogle Scholar
- Partington GA, Patient RK: Phosphorylation of GATA-1 increases its DNA-binding affinity and is correlated with induction of human K562 erythroleukaemia cells. Nucleic Acids Res 1999, 27: 1168–1175. 10.1093/nar/27.4.1168PubMed CentralView ArticlePubMedGoogle Scholar
- Crossley M, Orkin SH: Phosphorylation of the erythroid transcription factor GATA-1. J Biol Chem 1994, 269: 16589–16596.PubMedGoogle Scholar
- Towatari M, Ciro M, Ottolenghi S, Tsuzuki S, Enver T: Involvement of mitogen-activated protein kinase in the cytokine-regulated phosphorylation of transcription factor GATA-1. Hematol J 2004, 5: 262–272. 10.1038/sj.thj.6200345View ArticlePubMedGoogle Scholar
- Zhao W, Kitidis C, Fleming MD, Lodish HF, Ghaffari S: Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. Blood 2006, 107: 907–915. 10.1182/blood-2005-06-2516PubMed CentralView ArticlePubMedGoogle Scholar
- Onoyama I, Tsunematsu R, Matsumoto A, Kimura T, de Alborán IM, Nakayama K, Nakayama KI: Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med 2007, 204: 2875–2888. 10.1084/jem.20062299PubMed CentralView ArticlePubMedGoogle Scholar
- Matsuoka S, Oike Y, Onoyama I, Iwama A, Arai F, Takubo K, Mashimo Y, Oguro H, Nitta E, Ito K, Miyamoto K, Yoshiwara H, Hosokawa K, Nakamura Y, Gomei Y, Iwasaki H, Hayashi Y, Matsuzaki Y, Nakayama K, Ikeda Y, Hata A, Chiba S, Nakayama KI, Suda T: Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Gene Dev 2008, 22: 986–991. 10.1101/gad.1621808PubMed CentralView ArticlePubMedGoogle Scholar
- Aifantis I, Raetz E, Buonamici S: Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008, 8: 380–390. 10.1038/nri2304View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.